Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Isotope & Radiation Corp. ( (HK:1763) ) has issued an update.
China Isotope & Radiation Corporation reported 2025 revenue of RMB7.19 billion, down 5.1% year on year, mainly due to delayed centralized procurement of Class A large-scale nuclear medicine equipment. Net profit fell 24.4% to RMB664.5 million, with profit attributable to shareholders down 19.5% to RMB327.4 million, while the board recommended a final cash dividend of RMB0.2264 per share.
Excluding additional tax and late payment penalties incurred by a subsidiary, net profit attributable to the parent would have risen 12.5% to RMB457.4 million, indicating healthier underlying operations than headline figures suggest. The results highlight short-term pressure from procurement delays and tax-related items, but also show resilient core profitability and continued shareholder returns through dividends, factors closely watched by investors evaluating the company’s earnings quality and outlook.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a Chinese joint stock company specializing in nuclear medicine and radiation-related products and equipment. The group focuses on supplying nuclear medicine equipment and associated medical technologies, serving hospitals and healthcare institutions in its domestic market and potentially abroad.
Average Trading Volume: 195,752
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.58B
For an in-depth examination of 1763 stock, go to TipRanks’ Overview page.